Week 1 HW: Final Project Ideas

-> What do you want to make? → Ganoderic acid -> What living system could make it? → Yeast (S.cerevisae) -> How could automation help you make it? Automation of process to handle liquid handlers for cloning and transformation and extraction. -> What would it take to make it at a meaningful scale? The time and precission

Include in detail:

(1) What you would like to biomanufacture and why?

The objective of the project is to engineer a microbial chassis (e.g., Saccharomyces cerevisiae ) for the heterologous biosynthesis of Ganoderic Acid, specifically targeting highly bioactive, structurally defined variants such as Ganoderic Acid A (GAA) or Ganoderic Acid T (GAT).

Bio chemically, ganoderic acids are tetracyclic triterpenoids naturally synthesized by the basidiomycete fungus Ganoderma lucidum (Reishi). The biomanufacturing output will be an engineered yeast strain capable of converting simple carbon sources (e.g., glucose) into targeted ganoderic acid variants through the upregulation of the endogenous mevalonate (MVA) pathway and the introduction of heterologous cytochrome P450 monooxygenases (CYPs).

The immediate beneficiaries of this technology are the pharmaceutical and functional nutraceutical industries, ultimately serving patients with chronic metabolic conditions, hepatic diseases, and specific oncology profiles.

Pharmacological Importance: Ganoderic acids are the primary bioactive constituents responsible for the therapeutic effects of G. lucidum. Extensive pharmacological profiling demonstrates their efficacy as:

-> Anti-tumor agents: Mediated via induction of apoptosis and inhibition of angiogenesis.

-> Metabolic regulators: Specifically through the competitive inhibition of HMG-CoA reductase (modulating cholesterol synthesis) and 5$\alpha$-reductase.

-> Hepatoprotective compounds: Mitigating liver injury via potent antioxidant mechanisms.

Limitations of Agricultural Extraction (Current Status) -> Temporal Inefficiency: Traditional cultivation of G. lucidum fruiting bodies requires an extended agricultural cycle of 3 to 5 months.

-> Low Target Yield: Assuming standard solid-state cultivation, total triterpenoid accumulation in dried fruiting bodies is strictly bounded between 0.5% and 2.0% (w/w).

-> Downstream Processing (DSP) Burden: The native fungus produces over 130 structurally similar triterpenoid analogs. Isolating a single target molecule (e.g., GAA) to pharmaceutical grade (>98% purity) requires exhaustive, solvent-intensive chromatographic separations, driving up production costs and environmental impact.

Unviability of Chemical Synthesis Ganoderic acids possess a complex tetracyclic backbone with multiple stereocenters and position-specific oxygenation (e.g., sequential oxidations at C-3, C-7, C-11, C-15, C-22). De novo chemical synthesis requires highly complex protonation/deprotonation steps, therefore, chemical syntheis is economically and thermodynamically unviable for commercial scale-up.

Denovo Biomanifacturing Advantage and Feasabillity Heterologous biomanufacturing directly addresses these bottlenecks by transitioning production from macroscopic farming to precision fermentation.

-> Accelerated Production Cycle: Engineering S. cerevisiae shifts the production timeline from 150 days (fungal growth) to a standard aerobic bioprocess of 3 to 7 days.

-> Metabolic Precision: By expressing the specific CYPs and Cytochrome P450 reductases (CPRs) required for the oxidation of the lanosterol precursor, the engineered chassis acts as a “molecular factory” dedicated to a single ganoderic acid variant. This drastically reduces the analog noise, shifting the DSP from complex fraction separation to straightforward target purification.

-> Transitioning Ganoderic acid from an agricultural extract to a biomanufactured API (Active Pharmaceutical Ingredient) represents a critical step in access to high-value, plant- and fungi-derived therapeutics.

(2) What living system would you use? The primary living-system chassis selected for the biomanufacturing of Ganoderic Acid is the eukaryotic yeast Saccharomyces cerevisiae. The downstream conversion of the intermediate lanosterol into Ganoderic acid relies on multiple heterologous Cytochrome P450 monooxygenases (CYPs) and their associated Cytochrome P450 reductases (CPRs). These enzymes are membrane-bound and require insertion into the endoplasmic reticulum (ER) for proper folding and electron transfer—a cellular architecture present in yeast but absent in prokaryotes like E. coli. Furthermore, S. cerevisiae possesses a robust, natively expressed mevalonate (MVA) pathway that naturally produces high fluxes of sterol precursors.

Following are the exclusive feature of Saccharomyces cerevisiae that make it perfect organism to produce Ganoderic acid

-> Native Central Metabolism: Glycolysis catabolizes glucose into pyruvate, which is decarboxylated to Acetyl-CoA.

-> Native MVA and Sterol Pathway: Acetyl-CoA is sequentially condensed to form the C30 intermediate squalene. Squalene is epoxidized by native squalene epoxidase (ERG1) and cyclized by native lanosterol synthase (ERG7) to form lanosterol, the tetracyclic branch point.

-> Engineered Heterologous Pathway: Native sterol flux downstream of lanosterol (towards ergosterol) is transcriptionally downregulated. The accumulated lanosterol is shunted into a synthetic pathway composed of introduced Ganoderma lucidum CYPs. These enzymes catalyze successive regiospecific oxidations (e.g., at C-3, C-7, C-11, C-15) to yield the final targeted Ganoderic Acid variant (e.g., Ganoderic Acid A).

(3) How would you use automation? The automation platform will be used to execute two highly repetitive and error-prone stages of the Design-Build-Test-Learn (DBTL) cycle:

-> Automated DNA Assembly (The “Build” Phase): The liquid handler will automate the combinatorial Golden Gate assembly of multi-gene plasmids. We will construct a library of genetic circuits pairing the required Ganoderma lucidum CYPs and CPRs with a characterized library of yeast promoters (e.g., varying constitutive strengths like pTEF1, pPGK1, pHXT7).

-> High-Throughput Culturing and Extraction (The “Test” Phase): Post-transformation, the robot will manage continuous micro-culturing in 96-deep-well plates. Because ganoderic acids are highly hydrophobic and typically require organic extraction (e.g., utilizing ethyl acetate or dodecane), the liquid handler will automate the precise dispensing of solvents for targeted metabolite extraction and the preparation of the plates for subsequent high-throughput LC-MS screening.

(4) How much would you need to make, and how long would it take? Current proof-of-concept metabolic engineering efforts in Saccharomyces cerevisiae have achieved titers of approximately 14.5 mg/L for ganoderic acid precursors (such as HLDOA). For commercial viability, we assume intensive combinatorial optimization (as proposed in your automation section) will increase this titer to 5 g/L. This is a rigorous but realistic assumption, mirroring the industrial scale-up success of similar yeast-derived triterpenoids like artemisinic acid.

(a) How much? For the biomanufacturing of a novel Active Pharmaceutical Ingredient (API) like highly purified Ganoderic Acid (e.g., GAA), a commercially relevant and highly impactful initial scale is the production required to supply a large-scale Phase III clinical trial or an initial regional rollout for a specific clinical indication.

For this calculation, we will define the scale as supplying a therapeutic regimen for 10,000 patients for one calendar year. The targeted indication will be adjuvant therapy for hypercholesterolemia or chronic hepatic injury—conditions where Ganoderic acid’s mechanism of action (e.g., HMG-CoA reductase inhibition) is well documented in preclinical literature. To treat 10,000 patients annually with a daily 50 mg dose, we must manufacture approximately 203 kilograms of purified Ganoderic Acid API per year.

Engineering Context: Referring back to our previous fermentation calculations (where we demonstrated that a single 1,000 L bioreactor operating at a 5 g/L titer could produce 100 kg/year), achieving this 203 kg clinical scale would require incredibly modest infrastructure. Two 1,000 L bioreactors or a single 2,000 L vessel running a semi-continuous fed-batch process would easily satisfy the entire demand for this 10,000-patient cohort. This heavily reinforces the utilitarian motivation of the project: synthetic biology transforms the supply chain of complex phytochemicals from thousands of acres of agricultural land into a single room in a biomanufacturing facility.

(b) How long? It will take almost –days -> Strain Prototyping: ~365 days (12 months) -> Manufacturing Operations: 545 days (~18months) -> Total Project Timeline: ~30 months How much -> Operational Assumptions and Parameters:Target Purified API: 203 kg. -> Downstream Recovery Yield: 80% (0.80). -> Bioreactor Titer: 5 g/L (0.005 kg/L). -> Infrastructure: A single 2,000 L stainless-steel bioreactor.Working Volume: 80% of total capacity = 1,600 L per batch. -> Batch Cycle Time: 7 days (consisting of 5 days of active fermentation + 2 days for automated harvesting, CIP, and SIP).

5. What don’t you know yet? I dont know how to run the robots, bottlenecks in the project can be self compatabillity of yeast and how to precursor supply, although for this I will use the HPC cluster to prove them in silico but most of the time biology does not exactly mimic the ML models used for simulation. I think I need to learn how can I incorporate robotics to command them for optimization of protocols on which they work measure, and to experimentally determine to know whether your idea could actually work or not First of all I will do simulation of flux analysis and than will move for wetlab.

Referece AI Client used is Gemini Pro model